Klotho Neurosciences (KLTO) Competitors $0.28 -0.07 (-20.29%) (As of 11/14/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsSEC FilingsTrends KLTO vs. IKT, CYTH, CGTX, FNCH, CLDI, INAB, AIM, PMCB, EVAX, and TSBXShould you be buying Klotho Neurosciences stock or one of its competitors? The main competitors of Klotho Neurosciences include Inhibikase Therapeutics (IKT), Cyclo Therapeutics (CYTH), Cognition Therapeutics (CGTX), Finch Therapeutics Group (FNCH), Calidi Biotherapeutics (CLDI), IN8bio (INAB), AIM ImmunoTech (AIM), PharmaCyte Biotech (PMCB), Evaxion Biotech A/S (EVAX), and Turnstone Biologics (TSBX). These companies are all part of the "biological products, except diagnostic" industry. Klotho Neurosciences vs. Inhibikase Therapeutics Cyclo Therapeutics Cognition Therapeutics Finch Therapeutics Group Calidi Biotherapeutics IN8bio AIM ImmunoTech PharmaCyte Biotech Evaxion Biotech A/S Turnstone Biologics Klotho Neurosciences (NASDAQ:KLTO) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings. Do analysts rate KLTO or IKT? Inhibikase Therapeutics has a consensus price target of $6.50, indicating a potential upside of 175.42%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Klotho Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Klotho Neurosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Inhibikase Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in KLTO or IKT? 20.1% of Klotho Neurosciences shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 2.0% of Klotho Neurosciences shares are held by company insiders. Comparatively, 14.7% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community favor KLTO or IKT? Inhibikase Therapeutics received 9 more outperform votes than Klotho Neurosciences when rated by MarketBeat users. CompanyUnderperformOutperformKlotho NeurosciencesN/AN/AInhibikase TherapeuticsOutperform Votes990.00% Underperform Votes110.00% Does the media favor KLTO or IKT? In the previous week, Inhibikase Therapeutics had 6 more articles in the media than Klotho Neurosciences. MarketBeat recorded 7 mentions for Inhibikase Therapeutics and 1 mentions for Klotho Neurosciences. Klotho Neurosciences' average media sentiment score of 1.89 beat Inhibikase Therapeutics' score of 0.37 indicating that Klotho Neurosciences is being referred to more favorably in the media. Company Overall Sentiment Klotho Neurosciences Very Positive Inhibikase Therapeutics Neutral Is KLTO or IKT more profitable? Klotho Neurosciences' return on equity of -1.48% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Klotho NeurosciencesN/A -1.48% -0.34% Inhibikase Therapeutics N/A -194.17%-140.64% Which has higher valuation and earnings, KLTO or IKT? Klotho Neurosciences has higher earnings, but lower revenue than Inhibikase Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKlotho NeurosciencesN/AN/A$1.35MN/AN/AInhibikase Therapeutics$260K67.71-$19.03M-$2.88-0.82 SummaryInhibikase Therapeutics beats Klotho Neurosciences on 7 of the 12 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Klotho Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLTO vs. The Competition Export to ExcelMetricKlotho NeurosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.74M$3.06B$5.36B$8.88BDividend YieldN/A1.76%5.04%4.04%P/E RatioN/A46.30129.2617.44Price / SalesN/A426.291,250.8992.81Price / Cash0.91179.8139.3136.42Price / Book-0.134.296.275.87Net Income$1.35M-$42.42M$119.15M$224.97M7 Day Performance-29.49%-5.82%-1.11%-0.89%1 Month Performance-43.97%1.87%3.59%3.70%1 Year PerformanceN/A34.17%36.31%26.41% Klotho Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLTOKlotho NeurosciencesN/A$0.28-20.3%N/AN/A$4.74MN/A0.00N/AUpcoming EarningsPositive NewsGap DownIKTInhibikase Therapeutics2.704 of 5 stars$2.87-0.3%N/A+149.1%$21.41M$260,000.00-1.008News CoverageGap UpHigh Trading VolumeCYTHCyclo Therapeutics3.0782 of 5 stars$0.71-4.1%N/A-50.7%$20.38M$1.08M-0.819Short Interest ↓News CoverageCGTXCognition Therapeutics3.2178 of 5 stars$0.51flatN/A-47.9%$20.35MN/A-0.5420Short Interest ↑News CoverageFNCHFinch Therapeutics GroupN/A$11.70-0.8%N/A+196.1%$18.84M$110,000.00-1.33190Gap UpCLDICalidi Biotherapeutics2.6543 of 5 stars$1.68flatN/AN/A$18.67M$50,000.000.0041Earnings ReportNews CoverageGap DownHigh Trading VolumeINABIN8bio3.2532 of 5 stars$0.33-2.9%N/A-69.8%$15.53MN/A-0.4020Analyst ForecastShort Interest ↑News CoverageAIMAIM ImmunoTech1.2947 of 5 stars$0.23-4.1%N/A-44.3%$14.72M$200,000.00-0.4120News CoverageGap DownPMCBPharmaCyte Biotech1.2189 of 5 stars$1.76-2.2%N/A-15.8%$13.52MN/A2.672Short Interest ↑EVAXEvaxion Biotech A/S3.4446 of 5 stars$2.42-3.2%N/A-74.4%$13.50M$70,000.00-8.3449Short Interest ↓News CoverageGap DownTSBXTurnstone Biologics3.9275 of 5 stars$0.52-1.9%N/A-70.3%$12.35M$19.31M-0.1582Earnings ReportNews CoveragePositive NewsGap Down Related Companies and Tools Related Companies Inhibikase Therapeutics Competitors Cyclo Therapeutics Competitors Cognition Therapeutics Competitors Finch Therapeutics Group Competitors Calidi Biotherapeutics Competitors IN8bio Competitors AIM ImmunoTech Competitors PharmaCyte Biotech Competitors Evaxion Biotech A/S Competitors Turnstone Biologics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KLTO) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Klotho Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Klotho Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KLTO Stock Alerts